Mastino A, Favalli C, Grelli S, Innocenti F, Garaci E
Department of Experimental Medicine and Biochemical Sciences, University of Rome, Tor Vergata, Italy.
Cell Immunol. 1991 Mar;133(1):196-205. doi: 10.1016/0008-8749(91)90191-d.
We have investigated the effects of interleukin 2 (IL-2) on cytotoxic activity of spleen lymphocytes, from normal and cyclophosphamide (200 mg/kg) or B-16 melanoma suppressed mice, after in vitro or in vivo pretreatment with thymosin alpha 1 (TA1). The results of this study indicate that pretreatment in vitro (100 ng/ml for 1 hr) or in vivo (200 micrograms/kg/day for 4 days) with thymosin alpha 1 (TA1), significantly increased the IL-2 (from 100 to 500 U/ml) in vitro induced cytotoxic activity of spleen lymphocytes, collected from both normal and cyclophosphamide and tumor-suppressed animals, against both YAC-1 (NK sensitive) and MBL-2 (NK resistant) cell lines. The potential use in combination of these two different biological response modifiers, useful in enhancing the immunological responses to IL-2 of lymphocytes, may provide a novel model of immunotherapeutic intervention in cancer.
我们研究了白细胞介素2（IL-2）对正常小鼠、经环磷酰胺（200mg/kg）处理的小鼠或B-16黑色素瘤抑制小鼠脾脏淋巴细胞细胞毒性活性的影响，这些小鼠在体外用胸腺肽α1（TA1）预处理或在体内用胸腺肽α1（TA1）预处理。本研究结果表明，体外用胸腺肽α1（TA1）（100ng/ml处理1小时）或体内用胸腺肽α1（TA1）（200μg/kg/天，共4天）预处理，可显著提高体外诱导的脾脏淋巴细胞的IL-2（从100U/ml提高到500U/ml）细胞毒性活性，这些淋巴细胞取自正常小鼠、经环磷酰胺处理的小鼠和肿瘤抑制小鼠，它们对YAC-1（NK敏感）和MBL-2（NK抗性）细胞系均有细胞毒性。这两种不同的生物反应调节剂联合使用可能有助于增强淋巴细胞对IL-2的免疫反应，这可能为癌症免疫治疗干预提供一种新的模式。
